Cellceutix Corp., an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical needs, recently announced that the company has signed an agreement with Girindus America, Inc. to manufacture the active pharmaceutical ingredient of Kevetrinâ„¢. Cellceutix plans to use the active ingredient for toxicology studies and Phase 1 human trials.

Although the terms of the agreement were not disclosed, Kevetrin™ is being developed to treat certain cancers and the company has recently reported encouraging results in animal models of drug resistant lung cancers. Additional information regarding the company’s progress and results can be found online at www.cellceutix.com.

George Evans, CEO of Cellceutix, stated, “This is a big step toward our short-term goal of filing for an investigational new drug exemption ( IND ) with the FDA.” He continued, “We will use the material manufactured by Girindus to do the last animal studies needed for the filing of an IND , as well as for phase 1 human trials. We think Girindus will be an excellent partner for Cellceutix.”